Article | September 05, 2024

Navigating the Biosecure Act: Implications for Biotechnology and Pharmaceutical Companies

Read More

Article | September 04, 2024

DOJ Launches New Whistleblower Incentive Program

Read More

Article | August 29, 2024

Avoiding Post-Approval FDA Scrutiny: Drug Marketing Materials

Read More

Article | August 27, 2024

Kickbacks and Consequences: Lessons from the Innovasis Settlement

Read More

Article | August 14, 2024

FDA Faces Pressure to Enhance Oversight of Online Prescription Drug Promotions

Read More

Article | August 06, 2024

FDA Drafts Guidance on Correcting “Misinformation”

Read More

Article | August 01, 2024

FDA Unveils Criteria for Reporting Real-World Evidence (RWE) Submissions

Read More

Article | July 30, 2024

FDA-Gates Partnership: Advancing Disease Detection

Read More

Article | July 18, 2024

How to Prepare for and Respond to Government Investigations

Read More

Article | July 16, 2024

FDA Highlights the Promise of AI in Healthcare

Read More

Article | July 10, 2024

Privacy Summer School: 10 Things You Should Know About Privacy, Consent, and HIPAA

Read More

Article | July 08, 2024

U.S. Overturns Chevron Doctrine

Read More